| Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates |
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago. |
zacks.com |
2025-05-08 14:25:25 |
Czytaj oryginał (ang.) |
| Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates |
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update. |
globenewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Prime Drink Group Provides an Update to Its Subsidiary Restructuring |
MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to the termination of the forbearance agreements Roynat Inc. (“Roynat”), Financement Agricole Canada (“FAC”) and Banque Canadienne Impériale de Commerce (“CIBC” and together with Roynat and FAC, the “Creditors”) “principal creditors” have filed an application pursuant to Section 243 of the Bankruptcy and Insolvency Act (Canada) with the Superior Court, District of Montréal (the “Application”), to have a receiver appointed with respect to the assets of Prime's wholly-owned subsidiary, Triani Canada Inc (“Triani”). |
globenewswire.com |
2025-04-07 16:53:00 |
Czytaj oryginał (ang.) |
| Why Prime Medicine Stock Was Climbing Higher This Week |
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening. |
fool.com |
2025-03-20 20:48:00 |
Czytaj oryginał (ang.) |
| Why Prime Medicine Stock Is Soaring Today |
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. |
fool.com |
2025-03-19 16:56:30 |
Czytaj oryginał (ang.) |
| Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) |
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- |
globenewswire.com |
2025-03-18 09:00:00 |
Czytaj oryginał (ang.) |
| Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates |
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update. |
globenewswire.com |
2025-02-28 10:00:00 |
Czytaj oryginał (ang.) |
| Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference |
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm |
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-30 14:26:00 |
Czytaj oryginał (ang.) |
| Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies |
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies. |
seekingalpha.com |
2024-11-26 07:10:40 |
Czytaj oryginał (ang.) |
| Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics |
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Wilson Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson Disease pipeline landscape is provided which includes the disease overview and Wilson Disease treatment guidelines. The assessment part of the report embraces, in depth Wilson Disease commercial assessment and clinical assessment of the pipeline products under development. |
globenewswire.com |
2024-11-21 06:18:00 |
Czytaj oryginał (ang.) |
| Prime Medicine to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: |
globenewswire.com |
2024-11-06 18:00:00 |
Czytaj oryginał (ang.) |
| 12 High-Growth Stocks That Could Deliver Parabolic Returns |
These 12 innovative companies could deliver exponential returns over the next quarter century. |
fool.com |
2024-10-28 12:00:00 |
Czytaj oryginał (ang.) |
| Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress |
Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies |
globenewswire.com |
2024-10-24 12:00:00 |
Czytaj oryginał (ang.) |
| Why I Keep Buying These 14 Incredible Growth Stocks |
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. |
fool.com |
2024-10-16 13:45:00 |
Czytaj oryginał (ang.) |
| Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings |
-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases (AASLD), being held November 15-19, 2024 in San Diego. |
globenewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| PRME Stock Rises 11.8% on Collaboration With Bristol Myers |
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain. |
zacks.com |
2024-10-01 19:46:31 |
Czytaj oryginał (ang.) |
| Got $100? Consider Buying These 2 Penny Stocks in October |
You've likely heard that penny stocks are high-risk investments, and if so, you've heard right. |
247wallst.com |
2024-10-01 19:19:39 |
Czytaj oryginał (ang.) |
| Why Prime Medicine Stock Soared Nearly 12% Higher on Monday |
Changes are afoot at the company, and investors welcomed them. |
fool.com |
2024-09-30 22:08:17 |
Czytaj oryginał (ang.) |
| Crude Oil Moves Higher; Prime Medicine Shares Spike Higher |
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. |
benzinga.com |
2024-09-30 16:17:34 |
Czytaj oryginał (ang.) |
| Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline |
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies. |
benzinga.com |
2024-09-30 12:38:45 |
Czytaj oryginał (ang.) |
| Prime Medicine Unveils Strategically Focused Pipeline |
-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's Disease Program Toward Expected IND Application and/or CTA in 1H 2026 -- |
globenewswire.com |
2024-09-30 11:01:00 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks That Could Make You Richer |
Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the expanding commercial space industry with its small satellite launch services and vertical-integration strategy. |
fool.com |
2024-08-28 12:15:00 |
Czytaj oryginał (ang.) |
| Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? |
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results. |
zacks.com |
2024-07-31 18:57:10 |
Czytaj oryginał (ang.) |
| Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? |
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels. |
zacks.com |
2024-07-19 15:00:23 |
Czytaj oryginał (ang.) |
| Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio |
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX. |
zacks.com |
2024-06-21 13:25:24 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-05-30 14:55:20 |
Czytaj oryginał (ang.) |
| If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names |
Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero. |
investorplace.com |
2024-05-29 10:30:00 |
Czytaj oryginał (ang.) |
| Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio |
Alphabet manages more than $7 billion in equity investments, including a publicly traded portfolio. Its biggest holding competes with Microsoft's Github. |
fool.com |
2024-05-25 08:10:00 |
Czytaj oryginał (ang.) |